ID   NLRP3_RAT               Reviewed;        1035 AA.
AC   D4A523;
DT   10-MAY-2017, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2013, sequence version 2.
DT   02-OCT-2024, entry version 107.
DE   RecName: Full=NACHT, LRR and PYD domains-containing protein 3 {ECO:0000305};
DE            EC=3.6.4.- {ECO:0000250|UniProtKB:Q96P20};
GN   Name=Nlrp3 {ECO:0000312|RGD:1308314};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
CC   -!- FUNCTION: Sensor component of the NLRP3 inflammasome, which mediates
CC       inflammasome activation in response to defects in membrane integrity,
CC       leading to secretion of inflammatory cytokines IL1B and IL18 and
CC       pyroptosis. In response to pathogens and other damage-associated
CC       signals that affect the integrity of membranes, initiates the formation
CC       of the inflammasome polymeric complex composed of NLRP3, CASP1 and
CC       PYCARD/ASC. Recruitment of pro-caspase-1 (proCASP1) to the NLRP3
CC       inflammasome promotes caspase-1 (CASP1) activation, which subsequently
CC       cleaves and activates inflammatory cytokines IL1B and IL18 and
CC       gasdermin-D (GSDMD), promoting cytokine secretion and pyroptosis.
CC       Activation of NLRP3 inflammasome is also required for HMGB1 secretion;
CC       stimulating inflammatory responses (By similarity). Under resting
CC       conditions, ADP-bound NLRP3 is autoinhibited (By similarity). NLRP3
CC       activation stimuli include extracellular ATP, nigericin, reactive
CC       oxygen species, crystals of monosodium urate or cholesterol, amyloid-
CC       beta fibers, environmental or industrial particles and nanoparticles,
CC       such as asbestos, silica, aluminum salts, cytosolic dsRNA, etc. Almost
CC       all stimuli trigger intracellular K(+) efflux (By similarity). These
CC       stimuli lead to membrane perturbation and activation of NLRP3 (By
CC       similarity). Upon activation, NLRP3 is transported to microtubule
CC       organizing center (MTOC), where it is unlocked by NEK7, leading to its
CC       relocalization to dispersed trans-Golgi network (dTGN) vesicle
CC       membranes and formation of an active inflammasome complex. Associates
CC       with dTGN vesicle membranes by binding to phosphatidylinositol 4-
CC       phosphate (PtdIns4P). Shows ATPase activity (By similarity).
CC       {ECO:0000250|UniProtKB:Q8R4B8, ECO:0000250|UniProtKB:Q96P20}.
CC   -!- FUNCTION: Independently of inflammasome activation, regulates the
CC       differentiation of T helper 2 (Th2) cells and has a role in Th2 cell-
CC       dependent asthma and tumor growth. During Th2 differentiation, required
CC       for optimal IRF4 binding to IL4 promoter and for IRF4-dependent IL4
CC       transcription. Binds to the consensus DNA sequence 5'-GRRGGNRGAG-3'.
CC       May also participate in the transcription of IL5, IL13, GATA3, CCR3,
CC       CCR4 and MAF. {ECO:0000250|UniProtKB:Q8R4B8}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000250|UniProtKB:Q8R4B8};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066;
CC         Evidence={ECO:0000250|UniProtKB:Q8R4B8};
CC   -!- ACTIVITY REGULATION: Under resting conditions, NLRP3 binds ADP and is
CC       autoinhibited (By similarity). Inactive NLRP3 forms homodecameric
CC       double-ring cages that hide pyrin domains within NACHT-LRR rings to
CC       avoid premature activation. NLRP3 activation stimuli include
CC       extracellular ATP, nigericin, reactive oxygen species, crystals of
CC       monosodium urate or cholesterol, amyloid-beta fibers, environmental or
CC       industrial particles and nanoparticles, such as asbestos, silica,
CC       aluminum salts, cytosolic dsRNA, etc. Almost all stimuli trigger
CC       intracellular K(+) efflux. These stimuli lead to membrane perturbations
CC       that induce activation of NLRP3. Upon activation, NLRP3 is transported
CC       to microtubule organizing center (MTOC), where it is unlocked by NEK7,
CC       leading to its relocalization to dispersed trans-Golgi network (dTGN)
CC       vesicle membranes and recruitment of PYCARD/ASC for the formation of an
CC       active inflammasome complex. NEK7-activated NLRP3 forms a disk-shaped
CC       inflammasome. NLRP3 and PYCARD/ASC interact via their respective pyrin
CC       domains; interaction initiates speck formation (nucleation) which
CC       greatly enhances further addition of soluble PYCARD/ASC molecules to
CC       the speck in a prion-like polymerization process (By similarity).
CC       Clustered PYCARD/ASC nucleates the formation of CASP1 filaments through
CC       the interaction of their respective CARD domains, acting as a platform
CC       for CASP1 polymerization and activation. Active CASP1 then processes
CC       IL1B and IL18 precursors, leading to the release of mature cytokines in
CC       the extracellular milieu and inflammatory response (By similarity).
CC       NLRP3 inflammasome assembly is inhibited by IRGM, which impedes NLRP3
CC       oligomerization (By similarity). Specifically inhibited by sulfonylurea
CC       MCC950 (also named CP-456,773, CRID3), a potent and specific small-
CC       molecule inhibitor of the NLRP3 inflammasome that acts by preventing
CC       ATP hydrolysis (By similarity). {ECO:0000250|UniProtKB:Q8R4B8,
CC       ECO:0000250|UniProtKB:Q96P20}.
CC   -!- SUBUNIT: Sensor component of NLRP3 inflammasomes; inflammasomes are
CC       supramolecular complexes that assemble in the cytosol in response to
CC       pathogens and other damage-associated signals and play critical roles
CC       in innate immunity and inflammation. The core of NLRP3 inflammasomes
CC       consists of a signal sensor component (NLRP3), an adapter (PYCARD/ASC),
CC       which recruits an effector pro-inflammatory caspase (CASP1 and,
CC       possibly, CASP4 and CASP5). Homodecamer; inactive NLRP3 forms
CC       homodecameric double-ring cages that hide pyrin domains within NACHT-
CC       LRR rings to avoid premature activation. Interacts (via pyrin domain)
CC       with PYCARD/ASC (via pyrin domain); interaction is direct. Interacts
CC       (via LRR repeat domain) with NEK7 (via N-terminus); the interaction is
CC       required for the formation of the complex NLRP3:PYCARD, oligomerization
CC       of PYCARD/ASC and activation of CASP1 (By similarity). Interacts (via
CC       LRR repeat domain) with NR4A1/Nur77 (via N-terminus); the interaction
CC       is direct, requires activation of NR4A1 by its ligands NBRE-containing
CC       dsDNA and lipopolysaccharide, and stimulates the association of NLRP3
CC       with NEK7 for non-canonical NLRP3 inflammasome activation (By
CC       similarity). Interacts with CARD8; leading to inhibit formation of the
CC       NLRP3 inflammasome. Interacts with MEFV; this interaction targets NLRP3
CC       to degradation by autophagy, hence preventing excessive IL1B- and IL18-
CC       mediated inflammation (By similarity). Interacts with EIF2AK2/PKR; this
CC       interaction requires EIF2AK2 activity, is accompanied by EIF2AK2
CC       autophosphorylation and promotes inflammasome assembly in response to
CC       specific stimuli (By similarity). Interacts with GBP5 (via DAPIN
CC       domain); this interaction promotes inflammasome assembly in response to
CC       microbial and soluble, but not crystalline, agents. Interacts with PML
CC       (isoform PML-1) (via the leucine-rich repeat (LRR) domain); PML-
CC       mediated increase in NLRP3 inflammasome activation does not depend upon
CC       this interaction. Interacts (via NACHT domain) with DHX33 (via DEAH
CC       box); NLRP3 activation in presence of cytosolic dsRNA is mediated by
CC       DHX33. Interacts (via NACHT and LRR domains) with ARRB2; this
CC       interaction is direct and inducible by polyunsaturated fatty acids
CC       (PUFAs). Interacts (via NACHT domain) with DDX3X under both LPS-primed
CC       and inflammasome-activating conditions. Interacts with IRF4 (via the
CC       LRR domain); this interaction is direct and is required for optimal
CC       IRF4 binding to IL4 promoter and efficient IL4 transactivation during
CC       differentiation of Th2 helper T-cells. Interacts with MAVS; promoting
CC       localization to mitochondria and activation of the NLRP3 inflammasome.
CC       Interacts with MARK4; promoting localization of NLRP3 to the
CC       microtubule organizing center (MTOC) (By similarity). Interacts with
CC       TRIM50; this interaction promotes also NLRP3 oligomerization and
CC       subsequent inflammasome activation (By similarity). Interacts with
CC       IRGM; preventing NLRP3 inflammasome assembly and promoting NLRP3
CC       degradation (By similarity). {ECO:0000250|UniProtKB:Q8R4B8,
CC       ECO:0000250|UniProtKB:Q96P20}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q8R4B8}. Inflammasome
CC       {ECO:0000250|UniProtKB:Q8R4B8}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center {ECO:0000250|UniProtKB:Q8R4B8}. Golgi apparatus
CC       membrane {ECO:0000250|UniProtKB:Q8R4B8}. Endoplasmic reticulum
CC       {ECO:0000250|UniProtKB:Q8R4B8}. Mitochondrion
CC       {ECO:0000250|UniProtKB:Q8R4B8}. Secreted
CC       {ECO:0000250|UniProtKB:Q8R4B8}. Nucleus {ECO:0000250|UniProtKB:Q8R4B8}.
CC       Note=In macrophages, under resting conditions, mainly located in the
CC       cytosol and on membranes of various organelles, such as endoplasmic
CC       reticulum, mitochondria and Golgi: forms an inactive double-ring cage
CC       that is primarily localized on membranes. Upon activation, NLRP3 is
CC       transported to microtubule organizing center (MTOC), where it is
CC       unlocked by NEK7, leading to its relocalization to dispersed trans-
CC       Golgi network (dTGN) vesicle membranes for the formation of an active
CC       inflammasome complex. Recruited to dTGN vesicle membranes by binding to
CC       phosphatidylinositol 4-phosphate (PtdIns4P). After the induction of
CC       pyroptosis, inflammasome specks are released into the extracellular
CC       space where they can further promote IL1B processing and where they can
CC       be engulfed by macrophages. Phagocytosis induces lysosomal damage and
CC       inflammasome activation in the recipient cells. In the Th2 subset of
CC       CD4(+) helper T-cells, mainly located in the nucleus. Nuclear
CC       localization depends upon KPNA2. In the Th1 subset of CD4(+) helper T-
CC       cells, mainly cytoplasmic. {ECO:0000250|UniProtKB:Q8R4B8}.
CC   -!- DOMAIN: The pyrin domain (also called DAPIN domain or PYD) is involved
CC       in PYCARD/ASC-binding. {ECO:0000250|UniProtKB:Q96P20}.
CC   -!- DOMAIN: The FISNA domain is a critical mediator of NLRP3 conformational
CC       during NLRP3 activation. It becomes ordered in its key regions during
CC       activation to stabilize the active NACHT conformation and mediate most
CC       interactions in the NLRP3 disk. {ECO:0000250|UniProtKB:Q96P20}.
CC   -!- DOMAIN: The LRR domain mediates the interaction with IRF4, PML, NEK7
CC       and NR4A1/Nur77. {ECO:0000250|UniProtKB:Q8R4B8}.
CC   -!- DOMAIN: The KFERQ-like motifs mediate binding to HSPA8/HSC70 following
CC       NLRP3 paylmitoylation by ZDHHC12. {ECO:0000250|UniProtKB:Q96P20}.
CC   -!- PTM: Phosphorylation by MAPK8/JNK1 increases inflammasome activation by
CC       promoting deubiquitination by BRCC3 and NLRP3 homooligomerization.
CC       Phosphorylation at Ser-805 by CSNK1A1 prevents inflammasome activation
CC       by preventing NEK7 recruitment. Phosphorylation at Ser-5 in the pyrin
CC       domain inhibits homomultimerization of NLRP3 and activation of the
CC       NLRP3 inflammasome: dephosphorylation by protein phosphatase 2A (PP2A)
CC       promotes assembly of the NLRP3 inflammasome. Phosphorylation at Ser-293
CC       by PKD/PRKD1 promotes NLRP3 inflammasome assembly (By similarity).
CC       Phosphorylation by ERK1/MAPK3 promotes NLRP3 inflammasome assembly (By
CC       similarity). Phosphorylation by BTK (at Tyr-134, Tyr-138 and Tyr-166)
CC       in the region that mediates binding to phosphatidylinositol phosphate,
CC       promotes relocalization of NLRP3 and assembly of the NLRP3
CC       inflammasome. Phosphorylation at Tyr-860 inhibits NLRP3 inflammasome
CC       assembly: dephosphorylation by PTPN22 promotes inflammasome activation
CC       (By similarity). {ECO:0000250|UniProtKB:Q8R4B8,
CC       ECO:0000250|UniProtKB:Q96P20}.
CC   -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked
CC       polyubiquitination. Ubiquitination does not lead to degradation, but
CC       inhibits inflammasome activation. Deubiquitination is catalyzed by
CC       BRCC3 and associated with NLRP3 activation and inflammasome assembly.
CC       This process can be induced by the activation of Toll-like receptors
CC       (by LPS), through a non-transcriptional pathway dependent on the
CC       mitochondrial production of reactive oxygen species, and by ATP.
CC       Ubiquitinated by TRIM31 via 'Lys-48'-linked ubiquitination, leading to
CC       its degradation by the proteasome (By similarity). Ubiquitinated at
CC       Lys-689 by the SCF(FBXL2) complex, leading to its degradation by the
CC       proteasome (By similarity). Ubiquitinated by TRIM35 via 'lys-48' and
CC       'Lys-63'-linked ubiquitination leading to inhibition of NLRP3
CC       inflammasome activation (By similarity). {ECO:0000250|UniProtKB:Q8R4B8,
CC       ECO:0000250|UniProtKB:Q96P20}.
CC   -!- PTM: The disulfide bond in the pyrin domain might play a role in
CC       reactive oxygen species-mediated activation.
CC       {ECO:0000250|UniProtKB:Q96P20}.
CC   -!- PTM: Palmitoylation by ZDHHC12 inhibits the NLRP3 inflammasome by
CC       promoting NLRP3 degradation by the chaperone-mediated autophagy
CC       pathway. Following palmitoylation, HSPA8/HSC70 recognizes and binds the
CC       KFERQ-like motifs on NLRP3 and promotes NLRP3 recruitment to lysosomes,
CC       where it is degraded via the chaperone-mediated autophagy pathway in a
CC       LAMP2-dependent process. Palmitoylation by ZDHHC5 enhances its binding
CC       to NEK7 leading to inflammasome assembly and activation.
CC       Depalmitoylated by ABHD17A. {ECO:0000250|UniProtKB:Q96P20}.
CC   -!- PTM: Degraded via selective autophagy following interaction with IRGM.
CC       IRGM promotes NLRP3 recruitment to autophagosome membranes, promoting
CC       its SQSTM1/p62-dependent autophagy-dependent degradation.
CC       {ECO:0000250|UniProtKB:Q96P20}.
CC   -!- SIMILARITY: Belongs to the NLRP family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC123316; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001178571.1; NM_001191642.1.
DR   RefSeq; XP_006246515.1; XM_006246453.3.
DR   RefSeq; XP_017452567.1; XM_017597078.1.
DR   AlphaFoldDB; D4A523; -.
DR   SMR; D4A523; -.
DR   STRING; 10116.ENSRNOP00000004280; -.
DR   PhosphoSitePlus; D4A523; -.
DR   PaxDb; 10116-ENSRNOP00000004280; -.
DR   PeptideAtlas; D4A523; -.
DR   Ensembl; ENSRNOT00000004280.6; ENSRNOP00000004280.3; ENSRNOG00000003170.7.
DR   GeneID; 287362; -.
DR   KEGG; rno:287362; -.
DR   UCSC; RGD:1308314; rat.
DR   AGR; RGD:1308314; -.
DR   CTD; 114548; -.
DR   RGD; 1308314; Nlrp3.
DR   eggNOG; ENOG502SBIG; Eukaryota.
DR   GeneTree; ENSGT00940000162415; -.
DR   HOGENOM; CLU_002274_2_0_1; -.
DR   InParanoid; D4A523; -.
DR   OMA; NEMYFNY; -.
DR   OrthoDB; 55870at2759; -.
DR   Reactome; R-RNO-5689901; Metalloprotease DUBs.
DR   Reactome; R-RNO-844456; The NLRP3 inflammasome.
DR   PRO; PR:D4A523; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Bgee; ENSRNOG00000003170; Expressed in spleen and 18 other cell types or tissues.
DR   ExpressionAtlas; D4A523; baseline and differential.
DR   GO; GO:0061702; C:canonical inflammasome complex; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; ISO:RGD.
DR   GO; GO:0031021; C:interphase microtubule organizing center; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; ISO:RGD.
DR   GO; GO:0072559; C:NLRP3 inflammasome complex; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0043531; F:ADP binding; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0016887; F:ATP hydrolysis activity; ISS:UniProtKB.
DR   GO; GO:0140608; F:cysteine-type endopeptidase activator activity; ISO:RGD.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0060090; F:molecular adaptor activity; ISO:RGD.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; ISO:RGD.
DR   GO; GO:1901981; F:phosphatidylinositol phosphate binding; ISS:UniProtKB.
DR   GO; GO:0070273; F:phosphatidylinositol-4-phosphate binding; ISS:UniProtKB.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0035591; F:signaling adaptor activity; ISS:UniProtKB.
DR   GO; GO:0140299; F:small molecule sensor activity; ISS:UniProtKB.
DR   GO; GO:0002526; P:acute inflammatory response; ISO:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISO:RGD.
DR   GO; GO:0071224; P:cellular response to peptidoglycan; ISO:RGD.
DR   GO; GO:0098586; P:cellular response to virus; ISO:RGD.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; ISO:RGD.
DR   GO; GO:0051607; P:defense response to virus; ISO:RGD.
DR   GO; GO:0009595; P:detection of biotic stimulus; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0002523; P:leukocyte migration involved in inflammatory response; IEP:RGD.
DR   GO; GO:0002674; P:negative regulation of acute inflammatory response; ISO:RGD.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032691; P:negative regulation of interleukin-1 beta production; ISO:RGD.
DR   GO; GO:1901223; P:negative regulation of non-canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0044546; P:NLRP3 inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:0002720; P:positive regulation of cytokine production involved in immune response; ISO:RGD.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISS:UniProtKB.
DR   GO; GO:0032736; P:positive regulation of interleukin-13 production; ISO:RGD.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; ISO:RGD.
DR   GO; GO:0032754; P:positive regulation of interleukin-5 production; ISO:RGD.
DR   GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:2000321; P:positive regulation of T-helper 17 cell differentiation; ISO:RGD.
DR   GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; ISO:RGD.
DR   GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0002830; P:positive regulation of type 2 immune response; ISO:RGD.
DR   GO; GO:0051260; P:protein homooligomerization; ISS:UniProtKB.
DR   GO; GO:0051604; P:protein maturation; ISO:RGD.
DR   GO; GO:0050727; P:regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   CDD; cd00116; LRR_RI; 1.
DR   CDD; cd08320; Pyrin_NALPs; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 3.
DR   InterPro; IPR004020; DAPIN.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR029495; NACHT-assoc.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR041267; NLRP_HD2.
DR   InterPro; IPR050637; NLRP_innate_immun_reg.
DR   InterPro; IPR041075; NOD1/2_WH.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR45690; NACHT, LRR AND PYD DOMAINS-CONTAINING PROTEIN 12; 1.
DR   PANTHER; PTHR45690:SF19; NACHT, LRR AND PYD DOMAINS-CONTAINING PROTEIN 3; 1.
DR   Pfam; PF14484; FISNA; 1.
DR   Pfam; PF13516; LRR_6; 5.
DR   Pfam; PF05729; NACHT; 1.
DR   Pfam; PF17776; NLRC4_HD2; 1.
DR   Pfam; PF17779; NOD2_WH; 1.
DR   Pfam; PF02758; PYRIN; 1.
DR   SMART; SM01288; FISNA; 1.
DR   SMART; SM00368; LRR_RI; 9.
DR   SMART; SM01289; PYRIN; 1.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF52047; RNI-like; 1.
DR   PROSITE; PS50824; DAPIN; 1.
DR   PROSITE; PS51450; LRR; 5.
DR   PROSITE; PS50837; NACHT; 1.
PE   3: Inferred from homology;
KW   Activator; ATP-binding; Cytoplasm; Cytoskeleton; Disulfide bond;
KW   Endoplasmic reticulum; Golgi apparatus; Hydrolase; Immunity; Inflammasome;
KW   Inflammatory response; Innate immunity; Isopeptide bond;
KW   Leucine-rich repeat; Lipoprotein; Membrane; Mitochondrion;
KW   Nucleotide-binding; Nucleus; Palmitate; Phosphoprotein; Reference proteome;
KW   Repeat; Secreted; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1035
FT                   /note="NACHT, LRR and PYD domains-containing protein 3"
FT                   /id="PRO_0000439878"
FT   DOMAIN          1..93
FT                   /note="Pyrin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00061"
FT   DOMAIN          138..208
FT                   /note="FISNA"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          218..534
FT                   /note="NACHT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136"
FT   REPEAT          741..761
FT                   /note="LRR 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   REPEAT          770..791
FT                   /note="LRR 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   REPEAT          798..818
FT                   /note="LRR 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   REPEAT          827..848
FT                   /note="LRR 4"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   REPEAT          855..875
FT                   /note="LRR 5"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   REPEAT          884..905
FT                   /note="LRR 6"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   REPEAT          912..932
FT                   /note="LRR 7"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   REPEAT          941..962
FT                   /note="LRR 8"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   REPEAT          969..990
FT                   /note="LRR 9"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   REGION          129..132
FT                   /note="Required for binding to phosphatidylinositol 4-
FT                   phosphate (PtdIns4P)"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   MOTIF           353..357
FT                   /note="KFERQ-like motif 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOTIF           603..607
FT                   /note="KFERQ-like motif 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOTIF           797..801
FT                   /note="KFERQ-like motif 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOTIF           990..994
FT                   /note="KFERQ-like motif 4"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   BINDING         167
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   BINDING         224..231
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136"
FT   BINDING         520
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         5
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   MOD_RES         13
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         134
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         138
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         159
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   MOD_RES         166
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         199
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         293
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   MOD_RES         332
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         727
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         734
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         805
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         860
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   MOD_RES         1034
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   LIPID           836
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   LIPID           837
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   LIPID           843
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   DISULFID        8..106
FT                   /note="Redox-active"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   CROSSLNK        689
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   CROSSLNK        877
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
FT   CROSSLNK        972
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q96P20"
SQ   SEQUENCE   1035 AA;  118540 MW;  F182827924821C92 CRC64;
     MKMMSVRCKL AQYLEDLEDV DLKKFKMHLE DYPPEKGCVP IPRGQMEKAD HLDLATLMID
     FNGEEKAWGM AVWIFAAINR RDLWEKAKKD QPEWNDACTS NLSMVCQEDS LEEEWIGLLG
     YLSRISICKK KKDYCKIYRR HVRSRFYSIK DRNARLGESV DLNRRYTQLQ LVKEHPSKQE
     REHELLTIGR TKMWDRPMSS LKLELLFEPE DEHLEPVHTV VFQGAAGIGK TILARKIMLD
     WALGKLFKDK FDYLFFIHCR EVSLRAPKSL ADLIISCWPD PNPPVCKILC KPSRILFLMD
     GFDELQGAFD EHIEEVCTDW QKAVRGDILL SSLIRKKLLP KASLLITTRP VALEKLQHLL
     DHPRHVEILG FSEAKRKEYF FKYFSNELQA REAFRLIQEN EILFTMCFIP LVCWIVCTGL
     KQQMETGKSL AQTSKTTTAV YVFFLSSLLQ SRGGIEEHLF SAYLPGLCSL AADGIWNQKI
     LFEECDLRKH GLQKTDVSAF LRMNVFQKEV DCERFYSFSH MTFQEFFAAM YYLLEEEEEG
     VTVRKGPEGC SDLLNRDVKV LLENYGKFEK GYLIFVVRFL FGLVNQERTS YLEKKLSCKI
     SQQVRLELLK WIEVKAKAKK LQRQPSQLEL FYCLYEMQEE DFVQSAMGHF PKIEINLSTR
     MDHVVSSFCI KNCHRVKTLS LGFLHNSPKE EEEEKRGSQP LDQVQCVFPD PHVACSSRLV
     NCCLTSSFCR GLFSSLSTNQ SLTELDLSDN TLGDPGMRVL CEALQHPGCN IQRLWLGRCG
     LTHQCCFNIS SVLSSSQKLV ELDLSDNALG DFGVRLLCVG LKHLLCNLQK LWLVSCCLTS
     ACCQDLALVL SSNHSLTRLY IGENALGDSG VQVLCEKMKD PQCNLQKLGL VNSGLTSLCC
     SALTSVLKTN QNLTHLYLRS NALGDMGLKL LCEGLLHPDC KLQMLELDNC SLTSHSCWDL
     STILTHNQSL RKLNLSNNDL GDLCVVTLCE VLKQQGCLLQ SLQLGEMYLN CETKRTLEAL
     QEEKPELTVV FEISW
//
